<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00410150</url>
  </required_header>
  <id_info>
    <org_study_id>05-11-34-74-067</org_study_id>
    <nct_id>NCT00410150</nct_id>
  </id_info>
  <brief_title>Heliox-Powered Albuterol Therapy in the Treatment of Children Admitted With Acute Asthma Exacerbation</brief_title>
  <official_title>A Prospective, Randomized, Controlled, Single Center Trial of the Use of Heliox in Children Admitted to the Hospital With Status Asthmaticus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether heliox-powered albuterol nebulizer
      therapy will result in reduced inpatient length of stay in children hospitalized with acute
      asthma exacerbations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that heliox-powered albuterol nebulizer therapy will result in reduced
      inpatient length of stay in children hospitalized with acute asthma exacerbations. Severity
      of asthma will be characterized using a modified Becker Clinical Asthma Score (CAS) based
      upon the acuity of physical signs for four clinical characteristics (respiratory rate,
      wheezing, I/E ratio, and accessory muscle use). Scoring will occur at the time of enrollment
      and every 4 hours thereafter until the patient meets hospital discharge criteria. All scoring
      using the CAS will be performed by an independent physician, nurse or respiratory therapist
      blinded to the subject treatment arm. All children will receive standard cardiopulmonary
      monitoring and treatment, consisting of supplemental oxygen delivered as needed by either
      nasal cannula or face mask to maintain oxygen saturation &gt;90%, maintenance intravenous
      fluids, corticosteroid therapy and nebulized albuterol therapy. After written informed
      consent, eligible children will be randomized to one of two study groups using a sealed
      envelope technique:

      Group 1 (Heliox-Powered Albuterol) patients will receive all albuterol nebulizer treatments,
      including continuous therapy, powered by 70:30 Heliox.

      Group 2 (Oxygen-Powered Albuterol) patients will receive all albuterol nebulizer treatments,
      including continuous therapy, powered by 100% oxygen per usual standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was stopped after interim analysis and slow enrollment.
  </why_stopped>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>Hospital discharge</time_frame>
    <description>Time to discharge eligibility (hours)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Status Asthmaticus</condition>
  <arm_group>
    <arm_group_label>Group 1 (Heliox-powered albuterol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 (Heliox-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 70:30 Heliox.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Oxygen-powered albuterol)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 (Oxygen-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 100% oxygen per usual standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Helium-oxygen-driven albuterol nebulizer</intervention_name>
    <description>Subjects will be treated with continuous albuterol nebs with Heliox</description>
    <arm_group_label>Group 1 (Heliox-powered albuterol)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>Subjects will be treated with continuous albuterol nebs in oxygen</description>
    <arm_group_label>Group 2 (Oxygen-powered albuterol)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 2 -18 years;

          -  Previous history of asthma;

          -  Hospital admission for acute asthma exacerbation;

          -  Clinical asthma score greater than or equal to 3

        Exclusion Criteria:

          -  Less than 2 years old or over 18 years old;

          -  Known allergy or hypersensitivity to ÃŸ-agonists;

          -  Require mechanical ventilation (invasive or non-invasive);

          -  Require FiO2 &gt;0.4;

          -  Failure to obtain informed consent;

          -  Enrollment in another investigational drug or asthma protocol;

          -  Incipient respiratory failure including but limited to respiratory acidosis(pCO2&gt;60
             torr), altered mental status and/or excessive work of breathing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek S Wheeler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cincinnatichildrens.org</url>
    <description>Cincinnati Children's Hospital Medical Center</description>
  </link>
  <reference>
    <citation>Rivera ML, Kim TY, Stewart GM, Minasyan L, Brown L. Albuterol nebulized in heliox in the initial ED treatment of pediatric asthma: a blinded, randomized controlled trial. Am J Emerg Med. 2006 Jan;24(1):38-42.</citation>
    <PMID>16338507</PMID>
  </reference>
  <reference>
    <citation>Kim IK, Phrampus E, Venkataraman S, Pitetti R, Saville A, Corcoran T, Gracely E, Funt N, Thompson A. Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial. Pediatrics. 2005 Nov;116(5):1127-33.</citation>
    <PMID>16263999</PMID>
  </reference>
  <reference>
    <citation>Bandi V, Velamuri S, Sirgi C, Wendt J, Wendt R, Guntupalli K. Deposition pattern of heliox-driven bronchodilator aerosol in the airways of stable asthmatics. J Asthma. 2005 Sep;42(7):583-6.</citation>
    <PMID>16169793</PMID>
  </reference>
  <reference>
    <citation>Lee DL, Hsu CW, Lee H, Chang HW, Huang YC. Beneficial effects of albuterol therapy driven by heliox versus by oxygen in severe asthma exacerbation. Acad Emerg Med. 2005 Sep;12(9):820-7.</citation>
    <PMID>16141015</PMID>
  </reference>
  <reference>
    <citation>Ho AM, Lee A, Karmakar MK, Dion PW, Chung DC, Contardi LH. Heliox vs air-oxygen mixtures for the treatment of patients with acute asthma: a systematic overview. Chest. 2003 Mar;123(3):882-90. Review.</citation>
    <PMID>12628892</PMID>
  </reference>
  <reference>
    <citation>Kress JP, Noth I, Gehlbach BK, Barman N, Pohlman AS, Miller A, Morgan S, Hall JB. The utility of albuterol nebulized with heliox during acute asthma exacerbations. Am J Respir Crit Care Med. 2002 May 1;165(9):1317-21.</citation>
    <PMID>11991886</PMID>
  </reference>
  <reference>
    <citation>Haynes JM, Sargent RJ, Sweeney EL. Use of heliox to avoid intubation in a child with acute severe asthma and hypercapnia. Am J Crit Care. 2003 Jan;12(1):28-30.</citation>
    <PMID>12526234</PMID>
  </reference>
  <reference>
    <citation>Rose JS, Panacek EA, Miller P. Prospective randomized trial of heliox-driven continuous nebulizers in the treatment of asthma in the emergency department. J Emerg Med. 2002 Feb;22(2):133-7.</citation>
    <PMID>11858916</PMID>
  </reference>
  <reference>
    <citation>Dorfman TA, Shipley ER, Burton JH, Jones P, Mette SA. Inhaled heliox does not benefit ED patients with moderate to severe asthma. Am J Emerg Med. 2000 Jul;18(4):495-7.</citation>
    <PMID>10919545</PMID>
  </reference>
  <reference>
    <citation>Schaeffer EM, Pohlman A, Morgan S, Hall JB. Oxygenation in status asthmaticus improves during ventilation with helium-oxygen. Crit Care Med. 1999 Dec;27(12):2666-70.</citation>
    <PMID>10628607</PMID>
  </reference>
  <reference>
    <citation>Kass JE, Terregino CA. The effect of heliox in acute severe asthma: a randomized controlled trial. Chest. 1999 Aug;116(2):296-300.</citation>
    <PMID>10453854</PMID>
  </reference>
  <reference>
    <citation>Henderson SO, Acharya P, Kilaghbian T, Perez J, Korn CS, Chan LS. Use of heliox-driven nebulizer therapy in the treatment of acute asthma. Ann Emerg Med. 1999 Feb;33(2):141-6.</citation>
    <PMID>9922408</PMID>
  </reference>
  <reference>
    <citation>Kudukis TM, Manthous CA, Schmidt GA, Hall JB, Wylam ME. Inhaled helium-oxygen revisited: effect of inhaled helium-oxygen during the treatment of status asthmaticus in children. J Pediatr. 1997 Feb;130(2):217-24.</citation>
    <PMID>9042123</PMID>
  </reference>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2006</study_first_submitted>
  <study_first_submitted_qc>December 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2006</study_first_posted>
  <results_first_submitted>September 15, 2010</results_first_submitted>
  <results_first_submitted_qc>September 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 13, 2010</results_first_posted>
  <last_update_submitted>October 22, 2010</last_update_submitted>
  <last_update_submitted_qc>October 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Derek Wheeler</name_title>
    <organization>Cincinnati Children's Hospital Medical Center</organization>
  </responsible_party>
  <keyword>Status asthmaticus</keyword>
  <keyword>Asthma</keyword>
  <keyword>Helium</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Asthmaticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Heliox Group</title>
          <description>Patients randomized to the Heliox arm of the study</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Subjects randomized to the control arm of the study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20">2 study withdrawals (analyzed by intention-to-treat)</participants>
                <participants group_id="P2" count="17">3 study withdrawals (analyzed by intention-to-treat0</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Heliox Group</title>
          <description>Patients randomized to the Heliox arm of the study</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Subjects randomized to the control arm of the study</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" spread="0.8"/>
                    <measurement group_id="B2" value="8.2" spread="0.9"/>
                    <measurement group_id="B3" value="7.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Length of Stay</title>
        <description>Time to discharge eligibility (hours)</description>
        <time_frame>Hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heliox Group</title>
            <description>Patients randomized to the Heliox arm of the study</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects randomized to the control arm of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay</title>
          <description>Time to discharge eligibility (hours)</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.2" spread="8.7"/>
                    <measurement group_id="O2" value="63.4" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Heliox Group</title>
          <description>Patients randomized to the Heliox arm of the study</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Subjects randomized to the control arm of the study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Derek Wheeler</name_or_title>
      <organization>Cincinnati Children's Hospital Medical Center</organization>
      <phone>513-636-4239</phone>
      <email>derek.wheeler@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

